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Administration of Insulin by Continuous Ambulatory 
Peritonea I Dialysis 
Edwina Chan, Pharm.D., and Patricia A. Montgomery, Pharm.D. 
Many patients with diabetic nephropathy undergoing continuous ambulatory 
peritoneal dialysis (CAPD) use their peritoneal access to administer insulin. 
Compared with the subcutaneous route, intraperitoneal (IP) insulin may display 
more consistent absorption, produce more physiologic insulin concentrations, 
and be more convenient to administer. However, there are no well-controlled 
trials that have demonstrated a clinically significant difference in glycemic control 
between IP and subcutaneous administration. For patients who choose to begin 
IP insulin at the time CAPD is initiated, the starting dose is 2-3 times the 
previous subcutaneous dose. For patients previously stabilized on CAPD, the 
conversion factor may be less. Doses are divided equally between bags. Some 
authors recommend adding more insulin to bags with a higher concentration of 
dextrose. In addition, the dose should be decreased when added to a bag used 
for an overnight dwell. Exchanges performed during the day may be timed to 
start 30 minutes before a meal. Unless clinical trials demonstrate a difference in 
efficacy between subcutaneous and peritoneal insulin administration, the route 
will remain a matter of patient preference. 
(Pharmacotherapy 1993;13(5):455-460) 
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Diabetes mellitus is the third leading cause of 
end-stage renal disease (ESRD) in the United 
States. Approximately 5% of people with 
noninsulin-dependent diabetes mellitus (NIDDM) 
and 30-40% of those with insulin-dependent 
diabetes mellitus (IDDM) develop ESRD.’ Options 
for sustaining life in these patients include renal 
transplantation, hemodialysis, and peritoneal 
dialysis. Transplantation is an attractive option for 
all patients with ESRD, and is the treatment of 
choice when possible for those whose ESRD is 
due to diabetes mellitus.2 
For those who choose dialysis, continuous 
ambulatory peritoneal dialysis (CAPD) may offer 
From the Department of Pharmacy Services, University of 
Michigan Medical Center (both authors) and College of 
Pharmacy, University of Michigan (Dr. Montgomery), Ann Arbor, 
Michigan. 
Address reprint requests to Patricia A. Montgomery, 
Pharm.D., Department of Pharmacy Services, University of 
Michigan Medical Center, UH B2D301-0008, 1500 East Medical 
Center Drive, Ann Arbor, MI 481 09-0008. 
some advantages over hemodialysis, such as no 
need for routine vascular access, and continuous 
control of fluid status and blood pressure with a 
reduced risk of hemodynamic instability.’ In the 
United States, over 25% of patients beginning 
CAPD have ESRD secondary to diabetic 
nephr~pathy.~ Many of these patients who require 
insulin administer it through the peritoneal access. 
Rationale 
Compared with the subcutaneous route, several 
possible advantages to the administration of 
insulin by peritoneal dialysate have been cited. 
Absorption of insulin is erratic after subcutaneous 
admini~tration.~ One factor that may contribute to 
this is degradation at the site of in je~t ion.~ After 
subcutaneous administration of equivalent doses 
of insulin, the intrapatient variability in peak plasma 
concentration and extent of absorption is 20-30%.4 
The rate of absorption varies by as much as 50%,4’ 
but it is not clear that absorption pharmacokinetics 
after intraperitoneal administration are any more 
consistent. 
Peripheral hyperinsulinemia is another concern 
cited with subcutaneous insulin administration. 
Hepatic clearance of insulin released by the 
pancreas averages approximately 50O/0.~ After 
intraperitoneal administration, the majority of 
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insulin is delivered directly to the liver by the portal 
circulation, mimicking physiologic secretion . 7 3  
After subcutaneous injection, insulin reaches the 
peripheral circulation before the liver. Therefore, 
peripheral concentrations are relatively high in 
these patients compared with healthy individuals 
and also possibly those receiving intraperitoneal 
insulin.’ 
Hyperinsulinemia has been implicated as 
contributing to atherogenesi~.~, lo Its atherogenic 
potential is speculated to be due to its stimulation 
of lipid synthesis, with subsequent proliferation and 
deposition of lipid in arterial smooth muscle cells.” 
However, no clinical data associate high peripheral 
insulin concentrations with an increased risk of 
atherosclerotic disease. Therefore, this potential 
advantage of intraperitoneal insulin administration 
remains speculative. 
A final advantage of peritoneal insulin 
administration is convenience. Some patients may 
prefer this route over subcutaneous injections. 
Pharmacokinetics 
Drugs are generally absorbed from the 
peritoneal cavity by passive diffusion. The extent 
of absorption is dependent on an agent’s molecular 
weight, lipid solubility, protein binding, volume of 
distribution, ionic charge, and concentration 
gradient between the peritoneum and the 
peripheral circulation.” 
Drugs can be absorbed directly from the 
peritoneal cavity into the peritoneal viscera, 
including the liver, or into the portal cir~ulat ion.’~ 
Insulin that is absorbed into the portal system or 
directly into the liver undergoes significant and 
variable hepatic clearance. Therefore, peripheral 
concentrations are not ideal for evaluation of its 
absorption from the peritoneum.10 
Studies in dogs indicated that approximately 
26% of a dose of insul in is absorbed from 
peritoneal d i a 1 y ~ a t e . l ~  In three patients with 
diabetes who received insulin in their CAPD 
solution, the mean percentages absorbed after 2, 
4, and 8 hours were approximately 22%, 28%, and 
46%, re~pective1y.l~ Both of these studies used 
1251-labeled insulin to evaluate absorption kinetics. 
The influence of the insulin species source on 
intraperitoneal absorption has not been studied. 
The rate of insul in absorption after 
intraperitoneal administration depends on the 
transperitoneal concentration gradient and the 
absorptive surface area.16 Insulin may be detected 
in the peripheral blood within 15 minutes, with the 
peak concentration occurring at 15-60 minutes.17 
The onset of the hypoglycemic effect after instilling 
insulin and dialysate depends on the relationship 
between the insulin concentration and the glucose 
concentration; the blood glucose can decrease 
within 30 minutes.14, 15, l 8  
Because of case reports of decreased insulin 
requirements in patients with peritonitis, controlled 
animal studies were c ~ n d u c t e d . ’ ~ - ~ ~  Insulin 
disappeared more rapidly from the dialysate in rats 
with peritonitis than in those without peritonitis 
(mean half-life 84 f 18 min vs 107 f 28 min), but 
the difference was not significant.20 However, the 
uptake of glucose from dialysate was increased 
significantly (mean half-life 70 f 24 min vs 99 f 18 
min; p<0.05). Overall, the results did not suggest 
that an alteration in intraperitoneal insulin 
requirements due to permeability changes would 
be expected during peritonitis. The issue remains 
controversial. 
The effects of various dialysate dextrose 
concentrations and the presence of dialysate 
solution in the peritoneum on insulin transfer have 
also been studied.l8. 22 Two concentrations of 
dextrose in dialysate, 1.5% and 4.5%, were 
evaluated in nine patients with IDDM receiving 
CAPD.18 After insulin 20 U was injected 
intraperitoneally, the dialysate was instilled. The 
time to free peak insulin concentration was later 
after insulin was injected into an empty peritoneum 
than when it was followed by dialysate (45 vs 20 
min). After injection into an empty peritoneum, the 
insulin concentration was at all times higher than 
after injection with dialysate. The peak plasma 
insulin concentration was higher (p<0.05) after 
injection into an empty peritoneal cavity (55.6 f 
18.8 mU/L) compared with administration with 
either 1.5% dextrose (20 f 4.5 mU/L) or 4.5% 
dextrose (15.5 f 6.3 mU/L). The area under the 
plasma insulin concentration-time curve (AUC) was 
significantly greater when insulin was injected 
directly into an empty peritoneal cavity (3299 f 523 
mU min/L) than when it was administered as an 
additive to peritoneal dialysate solution containing 
either 1.5% dextrose (1428 f 116 mU min/L) or 
4.5% dextrose (1206 f 70 mU min/L) (peO.001). 
There was no significant difference in the AUC 
between the two concentrations of dextrose. 
However, absorption of increasing amounts of 
glucose is associated with increasing dextrose 
concentrations in the dialysate, and alterations in 
insulin requirements may result from adjustments 
in dextrose  concentration^.^^ Overall, these 
findings demonstrate that insulin is more 
extensively absorbed when administered into an 
empty peritoneal cavity than when instilled 
concurrently with dialysate, probably as the result 
of convective fluid movement into the peritoneal 
cavity when dialysate is instilled. 
Another factor that may affect absorption is the 
binding of insulin to the plastic tubing and bags in 
the CAPD ~ y s t e m . ~ ~ , ~ ~  When added to the 
dialysate solution, up to 20% of the total amount of 
insulin may be adsorbed to the polyvinyl chloride 
container and another 5% may be lost as a result 
of adsorption to the administration set and filter 
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device.23, 24 Adsorption decreases with increased 
insulin concentration and decreased temperat~re.~~ 
The loss due to adsorption may be compensated 
for by administering higher doses of insulin. Some 
authors recommend direct administration of insulin 
through the catheter rather than into the dialysate 
bag to avoid its binding to the surface of 
 container^.'^ 
In summary, intraperitoneal insulin is absorbed 
rapidly.” The extent of absorption is approx- 
imately 25-50% of an administered dose. In 
addition, absorption is not affected by the dextrose 
concentration of the dialysate and probably not by 
peritonitis. 
Clinical Studies 
No well-controlled studies have assessed the 
clinical utility of intraperitoneal insulin 
administration. A comparison of the efficacy of this 
route with subcutaneous injection should include 
patients with stable CAPD regimens. Both 
regimens should be maximized according to a 
defined algorithm. Measurement of glycemic 
control should include blood glucose and 
glycosylated hemoglobin concentrations. In 
addition, the study should be conducted over at 
least 6 weeks to allow for glycosylated hemoglobin 
concentrations to reach equilibrium. Several 
reports describing insulin administered by CAPD 
have been published, but none included rigorous 
controls, and many lacked adequate monitoring 
lntraperitoneal administration of insulin was 
studied in 20 patients with diabetes and ESRD.26 
Fourteen patients had IDDM; five of the remaining 
six had been previously treated with insulin. They 
were treated with CAPD for 2-36 months. Insulin 
was added to the dialysate bag immediately before 
the f luid was infused through an indwelling 
Tenckhoff catheter. The initial dose was 
determined according to the concentration of 
dextrose in the dialysate. It was then adjusted to 
achieve a fasting blood glucose concentration of 
7.7 mmol/L (140 mg/dl) and a postprandial 
concentration of less than 11.1 mmol/L (200 
mg/dl). Glycosylated hemoglobin concentrations 
were measured monthly. All patients were 
followed for more than 1 year. 
At the end of the study, the daily insulin dose 
ranged from 70-200 U. The mean glycosylated 
hemoglobin concentration was 182 f 38% of the 
normal value, which was similar to that in dialysis 
patients without diabetes. Hyperglycemia was 
reported to occur only in association with peritonitis 
or 1-3 days after discontinuation of dialysis; 
neither nonketotic hyperosmolar coma nor 
ketoacidosis was reported. Symptomatic 
hypoglycemia occurred rarely; however, two 
patients were admitted to the hospital with 
values.15.19.26-29 
hypoglycemia. lntraperitoneal administration of 
insulin was concluded to have potential for 
treatment of patients with diabetes on CAPD. 
Another study involved 24 patients with IDDM 
and ESRD.Ig The average duration of CAPD 
treatment prior to enrollment was 10.6 months. 
Insulin was injected through the catheter 
immediately before instillation of the new dialysate 
solution. Patients were maintained on a 
standardized diet, and the dose of insulin was 
adjusted according to the blood glucose 
concentrations of the previous day. Preprandial 
blood glucose concentrations were measured twice 
a day for 1 year. Serum glycosylated hemoglobin 
concentrations were measured at the start of the 
study and after 1 year of treatment. At the end of 
the study, the daily dose of insulin ranged from 
60-130 U. The mean fasting glucose concen- 
tration during treatment decreased from 11 mmol/L 
(198 mg/dl) to 5.8 mmol/L (104 mg/dl); this 
decrease was not significant. The mean serum 
glycosylated hemoglobin concentration at 1 year 
did not change significantly from that in the 
pretreatment period (1 0.3 f 2.0% vs 9.6 k 1.4%). 
Insulin requirements increased during episodes of 
peritonitis. The results of this study support the 
intraperitoneal route as an acceptable mode of 
insulin administration for patients with diabetes, but 
do not provide any evidence that it is superior to 
the subcutaneous route. 
Thirteen patients, seven with diabetes and six 
without, were enrolled in a study that evaluated 
glycemic control with intraperitoneal administration 
of insulin.27 Five of the seven patients with 
diabetes had IDDM and two had NIDDM. Insulin 
was given intraperitoneally to the patients with 
diabetes and subcutaneous insulin was 
discontinued. The dose was titrated depending on 
the time of day of the CAPD exchange and the 
concentration of dextrose in the dialysate. The 
duration of CAPD ranged from 2-7 months. 
Glycosylated hemoglobin and triglyceride 
concentrations were measured before and after 
CAPD. Both were higher after CAPD for al l  
patients; however, baseline levels were reported 
only for those with diabetes. The lack of reported 
data makes it difficult to assess the conclusion that 
intraperitoneal insulin can provide satisfactory 
glycemic control in patients with diabetes. 
Another trial assessing glycemic control studied 
the plasma concentrations of insulin and glucose in 
four patients with diabetes and ESRD who had 
been undergoing CAPD for 2-7 months.28 The 
patients received either intraperitoneal insulin 
alone (added to the dialysate) or in combination 
with subcutaneous insulin. The dose of 
intraperitoneal insulin was adjusted according to 
the dextrose concentration of the dialysate, the 
time of day of the exchange, and an algorithm 
based on blood glucose concentrations. There 
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were no dietary carbohydrate restrictions. After the 
dose was stabilized, blood glucose concentration 
was measured before each exchange. On the 
study day, subjects maintained their usual 
activities; serum glucose and insulin concen- 
trations were measured frequently. The frequency 
of glycosylated hemoglobin measurements and 
the values were not reported. Over 24 hours, 
mean plasma glucose concentrations for each 
patient ranged from 6.5 mmol/L (118 mg/dl) to 9.1 
mmol/L (1 64 mg/dl). Glycosylated hemoglobin 
values, available for only three patients, ranged 
from 8.3-9.4%. Clinically significant hypoglycemic 
episodes were not reported. The study suggests 
that intraperitoneal insulin may result in satisfactory 
control of hyperglycemia, at least over short 
periods of time. 
In another study, metabolic control was 
compared in six patients with IDDM receiving 
CAPD with intraperitoneal insulin (group l), six 
nondiabetic patients on CAPD (group 2), and six 
healthy subjects (group 3).29 The mean duration of 
CAPD was 7.2 months and 11.8 months for 
patients in groups 1 and 2, respectively. In groups 
1 and 2, four dialysis exchanges were performed 
daily, before meals and at bedtime. In patients 
with diabetes, regular insulin was added to the 
dialysis solution. The daily insulin doses ranged 
from 36-70 U (mean 59.5 U). In groups 1 and 2, 
blood glucose was determined 7 times/day- 
before meals (which coincide with daytime 
exchange times), after meals, and before the 
bedtime exchange. As expected, the mean blood 
glucose concentration was higher in group 1 than 
in groups 2 or 3: 9.4 f 8 mmol/L (169 f 14.4 
mg/dl), 6.5 f 3 mmol/L (117 f 5.4 mg/dl), and 4.9 f 
16 mmol/L (88.2 f 2 mg/dl), respectively (pcO.001). 
The mean glycosylated hemoglobin concentration 
was 6.7% in group 1 and 3.7% in group 2. The 
investigators concluded that intraperitoneal insulin 
may enable diabetic uremic patients to have 
satisfactory glycemic control throughout the day. 
The efficacy of intraperitoneal insulin was 
compared wifh that of subcutaneous insulin in 
three patients with diabetes and three ~ i t h o u t . ’ ~  All
six had previously been treated with hemodialysis 
or intermittent peritoneal dialysis. The study 
consisted of two 1 O-day phases. During phase 1, 
subjects with diabetes received subcutaneous 
insulin. In phase 2, CAPD was started and the 
subjects with diabetes were given intraperitoneal 
insulin at a daily dose 2.5 times the subcutaneous 
dose. The daily dose was divided equally among 
each of four dialysate bags with the exception of 
the evening bag, for which it was reduced by 25%. 
The dose was not altered based on dextrose 
concentration in the dialysate. After 1 week of 
CAPD, it was adjusted based on blood glucose 
concentrations from the previous week. 
Thereafter, it was left constant, and blood glucose 
concentrations were measured 4 times/day for the 
next 10 days. The mean daily baseline dose of 
subcutaneous insulin was 30 U (28-32 U). By the 
end of phase 2, the dose ranged from 2.4-4.8 
times the subcutaneous dose, with a mean daily 
dose of 107 U. 
The maximum variation in glucose concentration 
each day during phase 2 was significantly smaller 
than during phase 1, 2.8-4.3 mmol/L vs 7.1-11.8 
mmol/L, respectively (p<O.OOl). Glycosylated 
hemoglobin concentrations were not measured. It 
was concluded that intraperitoneal administration 
of insulin improved glycemic control compared with 
the subcutaneous route, although individual 
requirements varied considerably more. 
Thus administration of insulin in the peritoneal 
dialysate solution may be an alternative to 
subcutaneous insulin in patients with diabetes and 
ESRD; however, it must be noted that no well- 
controlled trials demonstrated a clinically significant 
difference in glycemic control between the two 
routes. Specifically, intraperitoneal administration 
has not been compared with several daily 
subcutaneous injections. 
Complications 
Aside from the usual adverse effects associated 
with insulin, other complications may result from 
intraperitoneal administration. One is subcapsular 
hepatic steatosis. In one series, steatosis was 
reported in 10 of 11 patients treated with 
intraperitoneal insulin, but in none of the 9 controls 
receiving CAPD without insulin.3o It was thought to 
be caused by the unusually high concentrations of 
insulin saturating the liver capsule with 
intraperitoneal administration. It was speculated 
that this disrupted the local regulation of lipid 
metabolism, resulting in an abnormal accumulation 
of triglycerides in the liver.31 
Another potential complication is peritonitis. The 
addition of insulin to the dialysate requires 
manipulation of the fluid, which could increase the 
frequency of bacterial contamination. This concern 
has not been borne out in clinical trials, possibly 
because the extensive training undertaken by 
patients using intraperitoneal insulin may improve 
their aseptic technique and reduce the risk of 
peritonitis. In one series, the frequency of 
peritonitis in patients receiving CAPD and 
intraperitoneal insulin was one episode/20.6 
patient-months.z6 The risk of a first episode by the 
end of the first year of treatment was 46%, which 
was not significantly different from that in patients 
without diabetes undergoing CAPD.261 32 E qua1 
frequency of peritonitis was reported in patients 
receiving intraperitoneal and subcutaneous 
insulin .33 
Hyperglycemia and hypoglycemia may also 
occur. In one series, hyperglycemia was rare and 
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was associated only with episodes of peritonitis.26 
No episodes of hypoglycemia were reported.26 
There is no reason to believe that either disorder 
occurs more often with the intraperitoneal than with 
the subcutaneous route. 
Dosage and Administration 
Most studies of intraperitoneal insulin involve 
CAPD rather than automated peritoneal dialysis 
(PD) using a cycling machine overnight; therefore, 
recommendations for CAPD in most studies do not 
apply to cycler PD. The customary treatment of 
patients with diabetes and ESRD receiving CAPD 
is to add regular insulin to each dialysate bag. In 
general, doses are divided equally among the 
bags; however, some authors recommend adding 
a higher amounts to bags with a higher 
concentration of 28 This may be 
necessary not because the dextrose concentration 
affects insulin absorption, but because of an 
increased carbohydrate load. 
The dose should be decreased when added to a 
bag used for an overnight dwell because of 
increased overall insulin absorption from the 
peritoneal cavity with a longer equilibrium time, and 
because of the tendency for reduced insulin 
requirements at night, both resulting in the danger 
of nocturnal hypoglycemia.26 Administration of 
insulin is normally timed with respect to dialysate 
exchanges. Some authors recommended that 
exchanges during the day be timed to start 30 
minutes before a meal to allow the peak insulin 
concentration to coincide approximately with the 
There is no basis for recommending a specific 
species of insulin for intraperitoneal injection. The 
species of regular insulin employed was reported 
in some of the studies; in most instances it was 
human insulin. The choice of species would be 
expected to have only a minimal influence on 
insulin's pharmacokinetics and pharmaco- 
dynamics. It should be made for intraperitoneal 
insulin with the same considerations as for 
subcutaneous administration. 
When switching from the subcutaneous to 
intraperitoneal route, the difference in absorption 
should be considered. Up to 100% of 
subcutaneous insulin is absorbed, compared with 
25-50% of intraperitoneal 1 4 7  l5 As in any 
patient starting CAPD, initially the dialysate may 
have to contain a high concentration of dextrose, 
and the increased carbohydrate load could be 
expected to necessitate a corresponding increase 
in the insulin dose. Taking these factors into 
consideration, the usually recommended starting 
dose is 2-3 times the subcutaneous dose in 
patients beginning intraperitoneal insulin at the 
time of starting CAPD.15 As when insulin is given 
subcutaneously, adjustments may be based on 
fasting, preprandial, and postprandial blood 
glucose concentrations. Home blood glucose 
monitoring is required. For patients who are 
stabilized on CAPD before initiation of 
intraperitoneal insulin, the subcutaneous dose 
should have been adjusted to account for the 
CAPD dextrose load. Therefore, in these patients, 
the conversion factor from subcutaneous to 
intraperitoneal insulin may be less. 
When patients receiving CAPD develop 
peritonitis it may be necessary to coadminister 
insulin with any one of several agents given 
intraperitoneally. Ampicillin, azlocillin, cephapirin, 
clindamycin, mezlocillin, piperacillin, and 
tobramycin retain greater than 90% activity at room 
temperature for 48 hours when added to dialysate 
solutions containing heparin and 34 
Cefotaxime, nafcillin, and vancomycin are 
compatible with insulin at 24 hours; however, the 
stability of the insulin in these solutions was not 
studied . No net he less, coadmi nist rat ion may st i I I 
be reasonable because the absorption of insulin 
can be monitored by blood glucose concentrations. 
Conclusion 
Administration of insulin in the peritoneal 
dialysate solution may be a viable option to 
subcutaneous insulin in patients with diabetes and 
ESRD undergoing CAPD. Possible advantages 
are convenience and avoidance of peripheral 
hyperinsulinemia. No trial performed to date has 
demonstrated a clinically significant difference in 
glycemic control between intraperitoneal and 
subcutaneous routes, or any benefit from an 
improved ratio of peripheral to portal insulin 
concentrations. lntraperitoneal administration has 
not been compared with intensive subcutaneous 
therapy. 
A possible disadvantage of intraperitoneal insulin 
is the necessity of relatively large doses, which 
would increase the cost of therapy. Unless 
controlled studies document a clinical difference 
between the intraperitoneal and subcutaneous 
routes, the decision remains largely a matter of 
patient preference. 
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